DrugDashboards

Rezzayo

rezafungin · REZAFUNGIN 200 mg/1 · Injection, Powder, Lyophilized, For Solution · Intravenous · Melinta Therapeutics, LLC

NDC 70842-0240-01 · 1 VIAL in 1 CARTON / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL · NDA · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Medicare Part B pays (ASP+6%)$11.00per billing unit (1 MG)HCPCS J0349 · Jul 1, 2026
  • Part D plans paid (avg)$1,962.13per dosage unitgross, before rebates — matched by drug name · 2024
  • Federal contracts pay (FSS)$1,516.08per unitMelinta Therapeutics, LLC · Jan 1, 2026

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$2,089.64
Reported to Texas DSHS · 2026 annual filing · Melinta Therapeutics, LLC

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 1 MG
$10.998
HCPCS J0349 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$262,598
172 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Is this a "specialty" drug?

There's no legal definition — it meets 3 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $2,637.61 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
NDA217417
TE code
Approval date
Mar 22, 2023
Patents / exclusivity
7 patents, 3 exclusivities
TypeNumber / codeExpires
exclusivityGAINMar 22, 2035
exclusivityODE-426Mar 22, 2030
exclusivityNCEMar 22, 2028
patent11197909Jul 14, 2038
patent11819533Jul 11, 2038
patent11712459Mar 15, 2037
patent8722619May 9, 2036
patent10702573Mar 14, 2033
patent9526835Mar 14, 2033
patent11654196Mar 2, 2032

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of rezafungin (Injection, Powder, Lyophilized, For Solution)

LabelerStrengthFirst seenLast seen
Melinta Therapeutics, LLCREZAFUNGIN 200 mg/1Jul 15, 2026Sep 2, 2026
Patheon Italia S.p.A.REZAFUNGIN 200 mg/1Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Rezzayo — NDC 70842-0240-01," retrieved September 3, 2026, https://drugdashboards.com/drug/70842024001.

Free to cite with attribution — see how the data is put together.